このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Arcellx マネジメント

マネジメント基準チェック /24

Arcellx'sの CEO はRami Elghandourで、 Jan2021年に任命され、の在任期間は 3.42年です。の年間総報酬は$ 24.96Mで、 2.4%給与と97.6%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.17%を直接所有しており、その価値は$ 4.96M 。経営陣と取締役会の平均在任期間はそれぞれ3年と3.8年です。

主要情報

Rami Elghandour

最高経営責任者

US$25.0m

報酬総額

CEO給与比率	2.4%
CEO在任期間	3.5yrs
CEOの所有権	0.2%
経営陣の平均在職期間	3.1yrs
取締役会の平均在任期間	3.9yrs

経営陣の近況

Recent updates

News Flash: Analysts Just Made A Sizeable Upgrade To Their Arcellx, Inc. (NASDAQ:ACLX) Forecasts

Jun 01

Rainbows and Unicorns: Arcellx, Inc. (NASDAQ:ACLX) Analysts Just Became A Lot More Optimistic

May 14

Is Arcellx (NASDAQ:ACLX) A Risky Investment?

May 12

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 01

Arcellx: Navigating The CAR T-Cell Revolution

Jan 30

Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues

Nov 18

Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts

May 10

CEO報酬分析

Arcellx の収益と比較して、Rami Elghandour の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$51m
Dec 31 2023	US$25m	US$601k	-US$71m
Sep 30 2023	n/a	n/a	-US$130m
Jun 30 2023	n/a	n/a	-US$183m
Mar 31 2023	n/a	n/a	-US$190m
Dec 31 2022	US$14m	US$565k	-US$189m
Sep 30 2022	n/a	n/a	-US$170m
Jun 30 2022	n/a	n/a	-US$95m
Mar 31 2022	n/a	n/a	-US$80m
Dec 31 2021	US$23m	US$470k	-US$65m

報酬と市場: Ramiの総報酬 ($USD 24.96M ) は、 US市場 ($USD 6.83M ) の同規模の企業の平均を上回っています。

報酬と収益: Ramiの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Rami Elghandour (45 yo)

3.5yrs

在職期間

US$24,964,306

報酬

Mr. Rami Elghandour serves as President, Chief Executive Officer and Chairman of the Board of Directors at Arcellx, Inc. since January 2021. Mr. Elghandour joined the Arcellx, Inc. on January 22, 2021. Pre...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Rami Elghandour	Chairman of the Board	3.5yrs	US$24.96m	0.17% $ 5.1m
Michelle Gilson	Chief Financial Officer	2.2yrs	US$3.55m	0.013% $ 378.3k
Christopher Heery	Chief Medical Officer	3.3yrs	US$3.86m	0.017% $ 507.7k
Narinderjeet Singh	Chief Technical Officer	2.8yrs	データなし	データなし
David Tice	Chief Scientific Officer	3yrs	データなし	データなし
Myesha Lacy	Chief Investor & Communications Officer	3.5yrs	データなし	データなし
Maryam Abdul-Kareem	General Counsel & Chief Legal Officer	2.1yrs	データなし	データなし
Kate Aiken	Chief People Officer	3.5yrs	データなし	データなし
Neeraj Teotia	Chief Commercial Officer	3.3yrs	US$2.00m	データなし
Aileen Fernandes	Chief Business Officer	2.1yrs	データなし	データなし

3.1yrs

平均在職期間

47yo

平均年齢

経験豊富な経営陣: ACLXの経営陣は経験豊富であると考えられます ( 3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Rami Elghandour	Chairman of the Board	3.5yrs	US$24.96m	0.17% $ 5.1m
David Lubner	Independent Director	3.9yrs	US$359.67k	0.040% $ 1.2m
Ali Behbahani	Independent Director	9.5yrs	US$355.17k	0.00079% $ 23.1k
Jill Carroll	Independent Director	6.8yrs	US$353.67k	データなし
Derek Yoon	Independent Director	4.3yrs	US$347.17k	データなし
Olivia Ware	Independent Director	2.2yrs	US$343.67k	0% $ 0
Kavita Patel	Independent Director	2.6yrs	US$344.67k	0% $ 0

3.9yrs

平均在職期間

50yo

平均年齢

経験豊富なボード: ACLXの取締役会は経験豊富であると考えられます ( 3.8年の平均在任期間)。

Arcellx マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$818k worth of stock

Arcellx, Inc., Annual General Meeting, May 24, 2024

Independent Director notifies of intention to sell stock

Recent updates

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Now 21% undervalued after recent price drop

New major risk - Revenue and earnings growth

News Flash: Analysts Just Made A Sizeable Upgrade To Their Arcellx, Inc. (NASDAQ:ACLX) Forecasts

Consensus revenue estimates increase by 14%

Chief Financial Officer notifies of intention to sell stock

Consensus revenue estimates increase by 11%

Rainbows and Unicorns: Arcellx, Inc. (NASDAQ:ACLX) Analysts Just Became A Lot More Optimistic

Is Arcellx (NASDAQ:ACLX) A Risky Investment?

New major risk - Revenue and earnings growth

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Chief Medical Officer exercised options and sold US$818k worth of stock

Arcellx, Inc., Annual General Meeting, May 24, 2024

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 10%

Price target increased by 13% to US$75.92

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 10.0% to US$72.27

Chairman of the Board recently sold US$2.4m worth of stock

New major risk - Revenue and earnings growth

Chairman of the Board notifies of intention to sell stock

Arcellx: Navigating The CAR T-Cell Revolution

Chairman of the Board recently sold US$1.6m worth of stock

Chairman of the Board notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Price target increased by 8.5% to US$65.18

Arcellx, Inc. Announces Continued Robust Long-Term Responses from its Cart-Ddbcma Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma At Ash

Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues

Arcellx, Inc. announced that it expects to receive $199.999991 million in funding from Gilead Sciences, Inc.

Price target increased by 9.5% to US$56.55

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 11%

Arcellx, Inc. Announces Oral Presentation for CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma At the 65th ASH Annual Meeting and Exposition

Consensus revenue estimates fall by 47%

Arcellx, Inc. Announces Partial Clinical Hold Lifted on Immagine-1 Phase 2 Clinical Program

Arcellx, Inc. Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program

Chairman of the Board recently sold US$115k worth of stock

Consensus EPS estimates fall by 365%

Price target increased by 12% to US$47.56

Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts

Price target increased by 9.2% to US$43.56

Chief Medical Officer notifies of intention to sell stock

Price target increased by 7.9% to US$42.33

Chief Medical Officer exercised options and sold US$404k worth of stock

Chief Medical Officer notifies of intention to sell stock

Arcellx, Inc. announced that it has received $100.000004 million in funding from Gilead Sciences, Inc.

Insider recently sold US$51k worth of stock

Insider recently sold US$51k worth of stock

Chief Medical Officer exercised options and sold US$231k worth of stock

Arcellx, Inc. Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress

Companies Like Arcellx (NASDAQ:ACLX) Are In A Position To Invest In Growth

High number of new directors

Arcellx: The Best Is Yet To Come

Arcellx, Inc. announced delayed 10-Q filing

Arcellx GAAP EPS of -$0.88

Arcellx down 9% on day lock-up period ends

We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely

Arcellx, Inc.(NasdaqGS:ACLX) dropped from Russell 2000 Growth Index

Arcellx: Speculative Buy For Their 'Best-In-Class' CAR-T Cell Therapy

Arcellx, Inc. Announces New Positive Clinical Data from the Ongoing Phase 1 Expansion Study of Its Novel, Autologous, CART-ddBCMA Therapy

High number of new directors

Arcellx, Inc. Appoints Michelle Gilson as Chief Financial Officer

Arcellx, Inc. Announces Resignation of Lewis T. Williams from Board of Directors

Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma

Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

High number of new directors

Arcellx, Inc. Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting

Arcellx Announces Pre-Clinical Data Presentation for ACLX-002 at the American Association for Cancer Research Annual Meeting 2022

マネジメント基準チェック /24